For the study, researchers tracked 1,070 kids aged 12 to 18 who were overweight or obese and also had a diagnosis of asthma.

Marketed as Exdensur, the ultra-long-acting biologic is the first of its kind, requiring only two injections per year to ...

Adolescents with overweight or obesity and asthma taking a GLP-1 agent had less risk of asthma exacerbations compared with ...

Small New Year's resolutions could make a big difference in the severity of people allergies and asthma, according to an ...

An asthma treatment that only requires patients to have two jabs a year to prevent life-threatening attacks will be available ...

This year’s top asthma and respiratory disorder story focused on the pushback from multiple advocacy groups following ...

Two replicate phase 3 trials of GB-0895, an anti-thymic stromal lymphopoietin antibody, are enrolling adults and adolescents ...

With a fresh endorsement from the FDA, the last of five major drug approvals has fallen into place for GSK in 2025. | Tuesday, the U.S. regulator greenlit GSK’s depemokimab, an ultra-long-acting ...

Paediatricians are observing a concerning rise in early-onset asthma among children, particularly in cities with poor air ...

More must be done to ensure that asthma patients get access to cutting-edge treatments, experts have said, after research ...

Children conceived through assisted reproductive technology (ART) were modestly more likely to develop asthma, allergic ...

On average, 10.6% of Louisiana adults reported ever being told by a health professional that they have asthma. These parishes ...